Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brynjar Mauseth

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Plos One|February 17, 2016
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 MelanomaLiv-Marie Eike, Brynjar Mauseth, Ketil André Camilio, et al.
Molecular Therapy Oncolytics|June 19, 2019
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular CarcinomaBrynjar Mauseth, Ketil André Camilio, Jihua Shi, et al.
Breast Cancer Research : BCR|January 24, 2019
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer modelKetil A Camilio, Meng-Yu Wang, Brynjar Mauseth, et al.
Scientific Reports|March 25, 2021
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancerKarianne Giller Fleten, J Johannes Eksteen, Brynjar Mauseth, et al.
Oncoimmunology|May 31, 2019
Tumor lysis with LTX-401 creates anticancer immunityWei Xie, Laura Mondragón, Brynjar Mauseth, et al.
Cell Death & Disease|October 25, 2018
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animalsHeng Zhou, Laura Mondragón, Wei Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid TumorsJames Spicer, Aurélien Marabelle, Jean-Francois Baurain, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Plos One|February 17, 2016
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 MelanomaLiv-Marie Eike, Brynjar Mauseth, Ketil André Camilio, et al.
Molecular Therapy Oncolytics|June 19, 2019
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular CarcinomaBrynjar Mauseth, Ketil André Camilio, Jihua Shi, et al.
Breast Cancer Research : BCR|January 24, 2019
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer modelKetil A Camilio, Meng-Yu Wang, Brynjar Mauseth, et al.
Scientific Reports|March 25, 2021
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancerKarianne Giller Fleten, J Johannes Eksteen, Brynjar Mauseth, et al.
Oncoimmunology|May 31, 2019
Tumor lysis with LTX-401 creates anticancer immunityWei Xie, Laura Mondragón, Brynjar Mauseth, et al.
Cell Death & Disease|October 25, 2018
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animalsHeng Zhou, Laura Mondragón, Wei Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid TumorsJames Spicer, Aurélien Marabelle, Jean-Francois Baurain, et al.
Pageof 1